Hui-liang Xue

ORCID: 0000-0001-9756-9524
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life
  • Neuroblastoma Research and Treatments
  • Neutropenia and Cancer Infections
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Hematopoietic Stem Cell Transplantation
  • Lung Cancer Research Studies
  • Hematological disorders and diagnostics
  • Chronic Myeloid Leukemia Treatments
  • Cancer, Hypoxia, and Metabolism
  • Retinoids in leukemia and cellular processes
  • Chronic Lymphocytic Leukemia Research
  • Immunodeficiency and Autoimmune Disorders
  • Sarcoma Diagnosis and Treatment
  • Cancer therapeutics and mechanisms
  • Folate and B Vitamins Research
  • Pharmaceutical studies and practices
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hemoglobinopathies and Related Disorders
  • Circadian rhythm and melatonin
  • Systemic Lupus Erythematosus Research
  • Adipose Tissue and Metabolism
  • Renal and related cancers

Qufu Normal University
2015-2023

Shanghai Jiao Tong University
2009-2022

Shanghai Children's Medical Center
2010-2022

North China University of Science and Technology Affiliated Hospital
2018

Children's Hospital of Fudan University
2014

Science and Technology Commission of Shanghai Municipality
2011

XinHua Hospital
2003-2006

MiR-1 has been reported to act as an inhibitory microRNA in gastric cancer (GC). This study aimed investigate the regulatory mechanism by which miR-1-3p blocks progression of GC targeting stanniocalcin 2 (STC2).The expression level was assessed via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Expressions STC2 were measured qRT-PCR and Western blot analysis. Proliferation invasion assays detected MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) transwell...

10.26355/eurrev_201910_19282 article EN PubMed 2019-10-01

Acute lymphoblastic leukemia (ALL) is the most common and curable malignant pediatric disease in children. In low- middle-income countries, however, economic factors prevent many patients from receiving complete treatment, even as government insurance entities lack data on costs for ALL therapies. Here, we analyzed overall therapies their constitutive elements.All cost information was drawn our hospital database. We of 45 newly diagnosed children with May 2005 to June 2006; 20 were...

10.1002/pbc.22127 article EN Pediatric Blood & Cancer 2009-07-04

Abstract Long‐term follow‐up data for childhood acute lymphoblastic leukemia (ALL) are scarce in China because of lacking population‐based and hospitalized registry system. This retrospective study, conducted at Shanghai's Children's Medical Center (SCMC), aimed to investigate the long‐term results ALL identify prognostic factors. The Pediatric Oncology Network Database, designed by St. Jude Research Hospital, USA, were used collect enrolled patients starting 2005. From 2005 2014, 1085...

10.1002/hon.2541 article EN Hematological Oncology 2018-08-22

This pilot study focused on whether flow cytometry (FCM) detection of minimal residual disease in bone marrow (BM) could predict the outcome patients with advanced neuroblastoma (NB).Fifty-seven stage 4 NB BM infiltration were enrolled this study. All them received NB-2001 protocol. samples examined for tumor cell contamination by both morphology and FCM CD45-FITC/CD81-PE/CD56-PECy5 monoclonal antibodies cocktail at diagnosis after courses chemotherapy.BM all positive FCM, from 30 became...

10.1097/coc.0b013e318210f51b article EN American Journal of Clinical Oncology 2011-05-03

This retrospective cohort study analysed the clinical characteristics and outcomes of patients with childhood lymphoblastic lymphoma (LBL) treated in Shanghai, China.From 2001 to 2010, 108 evaluable ≤16 years age who were newly diagnosed biopsy-proven LBL one three treatment protocols: CCCG-99, SCMC-T-NHL-2002, or LBL-CHOF-2006.Two had Stage I disease, 5 II, 55 III, 46 IV. The immunophenotype was T-cell 92 (85.2%) precursor B-cell 16 (14.8%). abandonment rate 11.5%. Twenty-five (23.2%)...

10.1002/pbc.24848 article EN Pediatric Blood & Cancer 2013-11-14

In order to investigate how photoperiod affects the expression of KiSS-1/G-protein-coupled receptor 54 (GPR54), hypothalamus, ovaries and testicles striped hamster were studied following treatment melatonin injection.We found that concentration in blood was consistent with treated photoperiods had significant effects on KiSS-1 expression, but effect GPR54 differed among tissues sexes.The relative gonads male female significantly higher than while difference between hypothalamus inconsistent...

10.4238/2015.october.29.10 article EN Genetics and Molecular Research 2015-01-01

Background: Molecular genetic alterations with prognostic significance have been described in childhood acute myeloid leukemia (AML). The aim of this study was to establish cost-effective techniques detect mutations FMS-like tyrosine kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and a partial tandem duplication within the mixed lineage (MLL-PTD) genes AML. Procedure: Ninety-nine children newly diagnosed AML were included study. We developed fluoresent dye SYTO-82 based high resolution melting...

10.3389/fped.2014.00096 article EN cc-by Frontiers in Pediatrics 2014-09-09

Abstract Purpose Studies of the association between body mass index (BMI) at diagnosis and treatment outcome in children with acute lymphoblastic leukemia (ALL) have yielded inconsistent results. Hence, we conducted a retrospective study large cohort Chinese ALL treated contemporary protocols. Patients Methods A total 1437 (62.1% male; median age 5.7 years, range: 2.3–16.3 years) were enrolled two consecutive clinical trials Shanghai Children's Medical Center. The rates overall survival,...

10.1002/cam4.5188 article EN cc-by Cancer Medicine 2022-09-27

The standard chemotherapy for acute myeloid leukemia (AML) is usually composed of anthracyclines and cytarabine. We previously reported that homoharringtonine (HHT) was incorporated into regimens pediatric AML with acceptable efficacy tolerable toxicity. treated newly diagnosed patients aged 0–18 years on the AML-SCMC-2009 protocol. A total 102 de novo were enrolled. All ten courses including double induction, high dose cytarabine consolidation, maintenance. cumulative HHT 165 mg/m2...

10.1080/08880018.2020.1820649 article EN Pediatric Hematology and Oncology 2020-10-05

Abstract In this study, we investigated the mitochondrial energy supply capacity and molecular mechanisms of apoptosis, fission, mitophagy in regulating degeneration testis striped dwarf hamsters ( Cricetulus barabensis ) under mild low temperature (15°C) short daylight (10 h:14 h) conditions. Results showed that moderate (ML), (SM), (SL) conditions, mitochondria were swollen cristae disrupted. Compared with & group (MM; 12 h:12 h, 22°C), number was significantly decreased SM SL groups....

10.1002/mrd.23632 article EN Molecular Reproduction and Development 2022-07-19

Abstract Background Mixed‐lineage leukemia ( MLL ) with multifarious partner genes leads to aggressive dismal outcomes. Methods Using panel‐based targeted sequencing, we examined 90 cases ‐rearranged ‐r) childhood acute leukemia, including 55 lymphoblastic (ALL) and 35 myeloid (AML). Results breakpoints complete rearrangements were identified. A total of 37.8% (34/90) patients displayed a single direct fusion gene, 15.6% (14/90) carried reciprocal fusion, 27.8% (25/90) had both alleles. The...

10.1002/pbc.27266 article EN Pediatric Blood & Cancer 2018-06-26

For the first time, we conducted a 2-center retrospective study to show efficacy of antithymocyte globulin (ATG)-Fresenius S plus cyclosporine treatment children with severe aplastic anemia. From March 1997 May 2011, total 124 patients (median age, 7.5 y; range, 1.5 16 y) from 2 centers acquired AA treated an immunosuppressive therapy (IST) regimen, consisting ATG-Fresenius (5 mg/kg per day for 5 d) and cyclosporine, were enrolled. The response rate was 55.6%. median time between IST 6 (0.5...

10.1097/mph.0000000000000170 article EN Journal of Pediatric Hematology/Oncology 2014-05-07
Coming Soon ...